2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Immunology, Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

1321 Diagnostic stewardship in suspected heparin-induced thrombocytopenia: Real-world patterns of PF4 testing, anticoagulation, and physician decision-making

Nikhila Sampath Kumar, MBBS, Nikhil Verma, MD2, Rahaf Omaish3, Tabitha Ranson, DO, MS4, Rohan Seth, MBBS5, Jacob Tanner Wooldridge, MD6, Cesar Gentille Sanchez, MD7
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
7 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Background: 
Heparin-induced thrombocytopenia (HIT) presents a diagnostic challenge in hospitalized patients, in whom thrombocytopenia is common and frequently multifactorial. The 4Ts score is recommended to estimate pretest probability and guide platelet factor 4 (PF4) antibody testing; however, real-world decisions regarding testing and anticoagulation may incorporate clinical factors not fully captured by structured scoring systems. We conducted a real-world study evaluating PF4 testing, 4Ts scoring, anticoagulation practices, and physician decision-making surrounding suspected HIT at an academic medical center. 

Methods: 
We conducted a single-center retrospective study of consecutive adult patients who underwent PF4-heparin antibody testing at the University of Arkansas for Medical Sciences between October 1, 2024 and September 30, 2025. Documented 4Ts scores at the time of testing were recorded when available, and retrospective 4Ts scores were independently calculated from the electronic medical record. Patients were categorized as low (≤3), intermediate (4–5), or high (6–8) pretest probability. Data collected included demographics, prior anticoagulant exposure, comorbid conditions associated with thrombocytopenia, platelet trends, and changes in anticoagulation. Primary outcomes evaluated the relationship between 4Ts score and initiation of direct thrombin inhibitors. Secondary outcomes included serotonin release assay utilization, thrombotic and bleeding events, and estimated testing costs. Concurrently, an institutional quality improvement initiative incorporating a physician survey was undertaken to evaluate HIT decision-making. 

Results: 

A total of 122 patients underwent PF4-heparin antibody testing during the study period. At the time of testing, documented 4Ts scores classified 25 (20.5%) patients as low, 77 (63.1%) as intermediate, and 20 (16.4%) as high pretest probability. In contrast, retrospective calculation classified 53 (43.4%) as low, 60 (49.2%) as intermediate, and 9 (7.4%) as high probability. Documented and retrospectively calculated risk categories were concordant in 58/122 cases (47.5%). 

Direct thrombin inhibitors (argatroban and bivalirudin) were initiated in 17 patients (13.9%) during HIT evaluation, with concordance between documented and retrospectively calculated 4Ts categories in 8/17 cases (47.1%).  Anticoagulation was withheld without initiation of argatroban in 72 patients (59.0%), demonstrating variation in anticoagulation management while HIT was being evaluated. Eight patients (6.6%) had positive PF4-heparin antibody testing, while HIT was confirmed by serotonin release assay in 1 patient (0.8% of the overall cohort). 

Preliminary responses from an ongoing intra-institutional physician survey demonstrated variability in diagnostic and therapeutic approaches to suspected HIT. When asked when they would obtain PF4 testing, 55.6% of physicians favored testing after excluding other causes of thrombocytopenia, 42.2% preferred to order PF4-heparin antibody testing within 48 hours of an atypical platelet decline, and 2.2% after >5 days of anticoagulation being held and without platelet recovery. In a standardized scenario of moderate suspicion for HIT with new thrombosis, 37.8% favored holding heparin, 28.9% said they would independently switch to an alternative anticoagulant and 28.9% opted to seek hematology consultation before changing therapy. PF4-heparin antibody testing in patients retrospectively classified as low probability accounted for approximately $23,250 in potentially avoidable testing costs over one year, excluding downstream costs of confirmatory testing, alternative anticoagulation, prolonged hospitalization, and anticoagulation-related complications. 

Conclusions: 

Given the potentially life threatening consequences of both missed and overtreated HIT, accurate risk assessment is critical. Concordant variability in real-world practice and physician survey responses suggest that challenges in HIT evaluation may extend beyond institution-specific workflows. These findings highlight a broader medical education gap and support multicenter evaluation, targeted education, and practical decision-support tools to improve diagnostic stewardship and patient safety.

Nikhila Sampath Kumar, MBBS: No relevant conflicts of interest to declare.